Article Contents ::
- 1 Details About Generic Salt :: Oral1
- 2 Main Medicine Class:: Hormone,contraceptive
- 3 Micronor, Nor-Q.D., Orvette Class: Hormone/contraceptive
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Oral1
Main Medicine Class:: Hormone,contraceptive
Micronor, Nor-Q.D., Orvette
Class: Hormone/contraceptive
Drugs Class ::
Action Alters cervical mucus, interferes with implantation and may suppress ovulation.
Indications for Drugs ::
Indications Prevention of pregnancy.
Drug Dose ::
Route/Dosage
ADULTS: PO 1 tablet daily, starting on first day of menstruation.
Contraindication ::
Contraindications Thrombophlebitis; thromboembolic disorders; history of deep vein thrombophlebitis; cerebral vascular disease; MI; coronary artery disease; known or suspected breast carcinoma; impaired liver function or disease; undiagnosed abnormal genital bleeding; known or suspected pregnancy; as diagnostic test for pregnancy.
Drug Precautions ::
Precautions
Pregnancy: Category X. Lactation: Excreted in breast milk. Depression: Use drug with caution in patients with history of depression. Fluid retention: Use with caution in patients with hypertension, convulsive disorders, migraines, asthma, cardiac, hepatic or renal dysfunction. Lipid disorders: Progestins may elevate LDL levels. Tartrazine sensitivity: Some products may contain tartrazine, which may cause allergic-type reaction in susceptible individuals.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
CV: Thrombophlebitis; cerebrovascular disorders. CNS: Depression; tiredness; fatigue. DERM: Rash with and without pruritus; acne; melasma or chloasma; photosensitivity. EENT: Retinal thrombosis. GU: Breakthrough bleeding; spotting; hypomenorrhea; amenorrhea; changes in cervical erosion and cervical secretions. HEPA: Cholestatic jaundice. RESP: Pulmonary embolism. OTHER: Breast changes; masculinization of female fetus; edema; weight change.
Drug Mode of Action ::
Action Alters cervical mucus, interferes with implantation and may suppress ovulation.
Drug Interactions ::
Interactions
Rifampin: Reduced plasma levels and pharmacologic effects of norethindrone.
Drug Assesment ::
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Perform baseline physical examination before beginning therapy.
- If spotting or breakthrough bleeding continues past second month, notify physician.
- Do not administer oral contraceptives to induce withdrawal bleeding as test for pregnancy.
|
Drug Storage/Management ::
Administration/Storage
- Administer at same time each day.
- Start on first day of menstruation.
- If GI upset occurs, administer with food.
Drug Notes ::
Patient/Family Education
- Advise patient to use additional method of birth control until after first wk of administration in initial cycle.
- Teach patient what to do if dose is missed. If 1 tablet is missed, take as soon as remembered and then take next tablet at regular time. If 2 consecutive tablets are missed; do not take missed tablets; discard and take next tablet at regular time. Use additional form of contraception until pregnancy is ruled out or menses occurs. If 3 consecutive tablets are missed, discontinue drug immediately. Use additional form of contraception until pregnancy is ruled out or menses occurs.
- Encourage patient who smokes to stop. Cardiovascular dysfunction and thromboembolic disease have been associated with use of oral contraceptives in patients who smoke.
- Advise patient that oral contraceptives may change fit of rigid contact lenses.
- Caution patient to avoid prolonged exposure to sunlight, and to use sunscreen or wear protective clothing to avoid photosensitivity reaction.
- Advise patient to wait ³ 3 mo after discontinuing oral contraceptives before trying to become pregnant.
- Instruct patient to report symptoms of blood clots (eg, pain, numbness, shortness of breath, visual disturbances).